Table 1.
Baseline demographics and disease characteristics
| Patients (n = 181) | |
|---|---|
| Median age, years (range) | 65.0 (37–83) |
| Female, n (%) | 93 (51) |
| Race, n (%) | |
| White | 145 (81) |
| Black/African American | 13 (7) |
| Asian | 9 (5) |
| Unknown | 12 (7) |
| ECOG performance status score, n (%) | |
| 0 | 104 (57) |
| 1 | 77 (43) |
| Clinical stage, n (%) | |
| IB | 18 (10) |
| IIA | 16 (9) |
| IIB | 55 (30) |
| IIIA | 70 (39) |
| IIIBa | 22 (12) |
| Histology, n (%) | |
| Non-squamous | 112 (62) |
| Squamous | 69 (38) |
| History of tobacco use, n (%) | |
| Never | 18 (10) |
| Current | 35 (19) |
| Former | 128 (71) |
| Median pack-years, n (range) | 22.75 (0–162.0) |
| PD-L1 TPS, n (%)b | |
| <1% | 69 (38) |
| 1–49% | 28 (15) |
| ≥50% | 49 (27) |
| Unknownc | 35 (19) |
| EGFR mutation, n (%)d | |
| Positive | 11 (6) |
| Negative | 154 (85) |
| Unknowne | 16 (9) |
| ALK rearrangement, n (%)d | |
| Positive | 6 (3) |
| Negative | 162 (90) |
| Unknownf | 13 (7) |
ALK, anaplastic lymphoma kinase; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; PD-L1, programmed death-ligand 1; TPS, tumor proportion score.
aSelect IIIB includes T3N2 or T4 (by size criteria, not by mediastinal invasion), per the American Joint Committee on Cancer Staging System (8th edition). bPD-L1 status was centrally determined by immunohistochemistry using the DAKO PD-L1 (22C3) assay. cThe large number of patients with ‘unknown’ PD-L1 status was attributable to missing samples and failed testing. dDetermined either locally or centrally from screening tissue (when adequate) or resected tumor tissue. eEGFR status was unknown in 16 patients (non-squamous, n = 5; squamous, n = 11). fALK rearrangement status was unknown in 13 patients (non-squamous, n = 5; squamous, n = 8).